Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYPH NASDAQ:HOWL NASDAQ:MNOV NASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYPHCypherpunk Technologies$0.68+1.4%$0.91$0.23▼$3.70$70.90M0.074.76 million shs1.87 million shsHOWLWerewolf Therapeutics$0.32-6.0%$0.47$0.27▼$2.38$16.54M0.3841,039 shs572,128 shsMNOVMediciNova$1.44+0.7%$1.35$1.17▼$1.96$70.39M0.6273,685 shs43,655 shsSCLXScilex$8.07+3.3%$7.38$4.20▼$34.27$66.32M1.6676,572 shs2.31 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYPHCypherpunk Technologies+1.35%+6.30%+30.11%-7.43%+134.38%HOWLWerewolf Therapeutics-5.99%+3.90%-18.43%-68.00%-70.40%MNOVMediciNova+0.70%+9.92%+9.92%+1.41%+14.29%SCLXScilex+3.33%+3.46%+15.29%+14.96%+34.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYPHCypherpunk Technologies$0.68+1.4%$0.91$0.23▼$3.70$70.90M0.074.76 million shs1.87 million shsHOWLWerewolf Therapeutics$0.32-6.0%$0.47$0.27▼$2.38$16.54M0.3841,039 shs572,128 shsMNOVMediciNova$1.44+0.7%$1.35$1.17▼$1.96$70.39M0.6273,685 shs43,655 shsSCLXScilex$8.07+3.3%$7.38$4.20▼$34.27$66.32M1.6676,572 shs2.31 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYPHCypherpunk Technologies+1.35%+6.30%+30.11%-7.43%+134.38%HOWLWerewolf Therapeutics-5.99%+3.90%-18.43%-68.00%-70.40%MNOVMediciNova+0.70%+9.92%+9.92%+1.41%+14.29%SCLXScilex+3.33%+3.46%+15.29%+14.96%+34.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYPHCypherpunk Technologies 2.00Hold$0.9033.33% UpsideHOWLWerewolf Therapeutics 2.14Hold$3.751,071.88% UpsideMNOVMediciNova 2.67Moderate Buy$8.33478.70% UpsideSCLXScilex 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest HOWL, SCLX, CYPH, and MNOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026CYPHCypherpunk Technologies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$0.907/1/2026CYPHCypherpunk Technologies Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$0.906/25/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026MNOVMediciNova Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/16/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026SCLXScilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/21/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D-)5/4/2026MNOVMediciNova D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.004/22/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/20/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYPHCypherpunk TechnologiesN/AN/AN/AN/A$1.83 per shareN/AHOWLWerewolf Therapeutics$1.88M8.27N/AN/A$0.51 per share0.63MNOVMediciNova$410K172.87N/AN/A$0.85 per share1.69SCLXScilex$30.25M2.26N/AN/A($24.94) per share-0.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYPHCypherpunk Technologies$4.82M-$0.02N/AN/AN/AN/A-48.33%-42.21%N/AHOWLWerewolf Therapeutics-$60.82M-$1.24N/AN/AN/AN/A-208.23%-75.12%8/13/2026 (Estimated)MNOVMediciNova-$12M-$0.23N/AN/AN/A-1,962.98%-27.28%-25.24%8/13/2026 (Estimated)SCLXScilex-$358.73M-$40.47N/AN/AN/A-1,110.17%N/A-143.55%9/2/2026 (Estimated)Latest HOWL, SCLX, CYPH, and MNOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026SCLXScilex-$0.3373-$4.76-$4.4227-$6.28$15.00 million$8.61 million5/14/2026Q1 2026CYPHCypherpunk Technologies-$0.0406-$0.46-$0.4194-$0.46N/AN/A5/14/2026Q1 2026MNOVMediciNova-$0.06-$0.05+$0.01-$0.05$0.19 million$0.19 million5/7/2026Q1 2026HOWLWerewolf Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/A4/10/2026Q4 2025SCLXScilex-$0.47-$4.60-$4.13-$4.60$12.10 million$4.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYPHCypherpunk TechnologiesN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYPHCypherpunk TechnologiesN/A27.2827.28HOWLWerewolf TherapeuticsN/A1.271.27MNOVMediciNovaN/A9.099.09SCLXScilexN/A0.080.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYPHCypherpunk Technologies30.46%HOWLWerewolf Therapeutics64.84%MNOVMediciNova9.90%SCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipCYPHCypherpunk Technologies3.50%HOWLWerewolf Therapeutics23.60%MNOVMediciNova14.00%SCLXScilex4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYPHCypherpunk Technologies40106.46 million102.74 millionOptionableHOWLWerewolf Therapeutics4048.60 million37.13 millionOptionableMNOVMediciNova1049.22 million42.33 millionOptionableSCLXScilex808.49 million8.11 millionNo DataHOWL, SCLX, CYPH, and MNOV HeadlinesRecent News About These CompaniesScilex Holding Company (SCLX) Stock Surges on $100M Investment Proposal from iHoldingJuly 6 at 11:51 AM | blockonomi.comScilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026July 6 at 11:35 AM | globenewswire.comScilex shares jump after securing $100 million strategic investment proposal (SCLX)July 6 at 10:09 AM | msn.comWhat's going on with Scilex Holding stock Monday?July 6 at 10:09 AM | msn.comScilex secures major growth capital equity investmentJuly 6 at 7:10 AM | tipranks.comScilex Holding Company Announces Binding Term Sheet for $100 Million Strategic Investment from iHolding Group LLPJuly 6 at 6:31 AM | quiverquant.comQScilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLPJuly 6 at 6:00 AM | globenewswire.comScilex Pursues Major Bitcoin Acquisition via Term SheetJune 29, 2026 | tipranks.comScilex Stockholders Approve Director Election and Equity PlanJune 24, 2026 | tipranks.comScilex Holding Company to List Dream Bowl Tokens on Biconomy Exchange Starting June 23, 2026June 16, 2026 | quiverquant.comQScilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026June 16, 2026 | globenewswire.comScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders ...June 12, 2026 | finance.yahoo.comScilex Holding Company Announces Dividend Payment Date for Semnur Pharmaceuticals Common StockJune 12, 2026 | quiverquant.comQScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesJune 12, 2026 | globenewswire.comScilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...June 5, 2026 | theglobeandmail.comScilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...June 4, 2026 | markets.businessinsider.comScilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesJune 4, 2026 | globenewswire.comScilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other ...May 22, 2026 | markets.businessinsider.comScilex Holding Company Declares Dividend of Semnur Pharmaceuticals Common Stock to ShareholdersMay 22, 2026 | quiverquant.comQScilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026May 22, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOWL, SCLX, CYPH, and MNOV Company DescriptionsCypherpunk Technologies NASDAQ:CYPH$0.68 +0.01 (+1.35%) As of 07/6/2026 04:00 PM EasternLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Werewolf Therapeutics NASDAQ:HOWL$0.32 -0.02 (-5.99%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$0.33 +0.01 (+3.75%) As of 05:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.MediciNova NASDAQ:MNOV$1.44 +0.01 (+0.70%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$1.44 0.00 (-0.35%) As of 07/6/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Scilex NASDAQ:SCLX$8.07 +0.26 (+3.33%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$7.82 -0.26 (-3.16%) As of 05:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
